Articles tagged with Cancer Medication
Researchers have discovered a new drug combination that disrupts two key signaling pathways that drive breast cancer growth, showing promise in treating the disease. The combination of rapamycin and dasatinib was found to be more effective than using either drug alone in killing tumors.
Breast cancer patients taking brand name aromatase inhibitors had higher discontinuation rates and nonadherence compared to those on generic AIs. Higher copayments of $15-$30 per month were also linked to discontinued use.
A recent study found that 43% of medicinal plants in Pakistan were naturally contaminated with toxins produced by moulds. The levels exceeded permissible limits in 70% of the samples, and 31% produced harmful toxins. This highlights a need for stricter regulation to protect people using herbal medicines.
A new drug, OTS964, can eradicate aggressive human lung cancers transplanted into mice by inhibiting the action of a protein overproduced by several tumor types. The drug was well-tolerated and effective when taken as a pill or injected intravenously.
Researchers at the Salk Institute have discovered a mechanism for cancer cells to become resistant to chemotherapy, which may lead to a new approach to treating cancer. The study found that variations in breast cancer cells' RNA enable the cancer to evolve and adapt more quickly than previously thought.
Researchers at NYU Langone Health have made breakthroughs in treating T-cell acute lymphoblastic leukemia by blocking the action of an enzyme called JMJD3. The treatment, GSKJ4, has shown promising results in mice and human lab cells, with cancer cells dying when treated with the experimental drug.
A novel strategy combining nanoparticle technology with FDA-approved photodynamic therapy has been developed to effectively kill deep-set cancer cells in vivo. The treatment uses low-power, deep-tissue-penetrating light to activate the cancer-killing drug, showing improved destruction of tumors with minimal damage to surrounding tissue.
E-cigarette regulation by FDA could shift smokers away from lethal cigarettes and save lives. Clean-nicotine products may replace traditional tobacco, reducing nicotine levels and flavorings.
The EMA is exploring alternative approaches to clinical trials in rare cancers, recognizing the challenges of small sample sizes and the need for innovative methods. These discussions aim to enhance the evidence base for treatments in rare cancer patients, who face limited treatment options.
The Basser Research Center has received $6.9 million in new grants to develop vaccines and therapies for patients at increased risk of breast and ovarian cancers. The funding will support multi-disciplinary collaboration efforts aimed at identifying new treatments.
Researchers at Imperial College London have developed a new cancer drug, DTP3, that selectively kills multiple myeloma cells without causing toxicity. The drug works by stopping the NF-kB pathway, which allows cancer cells to multiply, and has been awarded funding for clinical trials in patients with multiple myeloma.
University of Iowa researchers found a gene in an amoeba that functions similarly to the human PTEN gene, which suppresses tumor growth. They tested the gene in mice and found it fully overcompensated for defects caused by mutated PTEN genes, potentially leading to new cancer treatments.
Researchers identified a neuronal pathway blocked by cancer drug doxorubicin in snails and rats, which may be responsible for 'chemo brain'. The study suggests that another agent can counteract the effects, paving the way for new treatments to alleviate cognitive deficits in cancer patients.
Researchers at Dana-Farber Cancer Institute identified two previously unknown mutations in a cancer patient's DNA that led to an extraordinary response to the drug everolimus. The study highlights the potential of personalized medicine and may help develop new therapeutic strategies for other patients with similar mutations.
Dartmouth researchers have identified nine traits that predict single nucleotide polymorphism (SNP) reproducibility without relying on P-values. The Replication Score (RS) model can select SNPs for validation and prioritization, improving the accuracy of genetic association studies.
A new chemotherapy drug regimen has been shown to effectively control life-threatening immune responses in bone marrow transplant recipients. The short course of cyclophosphamide, combined with two other chemotherapy drugs, eliminates the need for six months of immunosuppressive treatment.
Recent trends in cancer drug spending show a significant increase, with hospitals profiting from discounted prices through the 340B program. Researchers found that hospitals serving more affluent communities increased their profits, while patients may not receive the intended discounts.
Weizmann Institute researchers found that cancer grows faster during the day and is suppressed at night due to hormonal fluctuations. Administering treatments in sync with the body's natural day-night cycle may improve their effectiveness.
Weian Zhao, a UCI stem cell scientist, has been awarded the prestigious NIH New Innovator Award to create stem cell-based detection methods for cancer. His project aims to engineer smart stem cell systems to target cancer cells and improve treatment outcomes.
The Kay Yow Cancer Fund has awarded a $100,000 young women's breast cancer research grant to the Knight Cancer Institute at Oregon Health & Science University. The grant will support research on non-steroidal anti-inflammatory drugs (NSAIDs) and their potential effectiveness in preventing metastasis of breast cancer in young women.
A team of researchers from InSilico Medicine has successfully mapped the molecular pathway for myeloid-derived suppressor cell (MDSC) cancer progression. The study identifies several proliferation and invasion-related pathways that are key to MDSC's immune-suppressive effects, opening up new avenues for therapy targeting these cells.
A phase 1 clinical trial of crizotinib against ROS1-positive lung cancer showed a 72% response rate and 19.2 months progression-free survival, suggesting potential for durable action against this subtype of lung cancer.
Researchers have found a targeted treatment, afatinib, that can stop the growth of aggressive womb cancer cells and shrink tumours. The drug targets faults in the HER2 gene, which lie at the heart of the cancer cells, offering new hope for patients with this rare but deadly form of cancer.
A gene mutation that causes a rare premature aging disease could lead to the development of drugs that block rapid cell division in cancer. Researchers discovered a protein mutation that inhibits telomerase, allowing for the potential treatment of cancer and bone marrow failure.
Montefiore Einstein Center for Cancer Care and Albert Einstein Cancer Center have been awarded a $3.4 million grant from the National Cancer Institute to conduct multi-site cancer clinical trials and research focused on reducing healthcare disparities in cancer care. The award will help change the burden of cancer, which is disproporti...
A study published in Journal of Clinical Oncology found that the 2005 Medicare law had no significant impact on reducing chemotherapy drug costs, contradicting economists' expectations. Instead, cancer care costs skyrocketed during the decade after the law passed.
The phase III trials indicate that anamorelin is safe and well-tolerated in treating symptoms of advanced non-small cell lung cancer anorexia-cachexia. Patients experienced improvements in lean body mass, body weight, and patient symptoms/concerns regarding appetite over 12 weeks.
Researchers found significant variations in approval times for cancer drugs between the US, Canada, and Europe, with patients in some regions waiting years longer than others. The study emphasizes the need for coordinated action to reduce disparities in drug access and improve patient outcomes.
Researchers at Imperial College London have created a 'global map' of proteins modified by the disease-causing enzyme N-myristoyltransferase (NMT), identifying over 100 previously unknown substrates. The study holds promise for new cancer treatments, with a potent drug-like molecule already identified to block NMT's activity.
Researchers have successfully delivered antibody mimics into cells using a disarmed version of anthrax toxin, offering a potential new approach for treating various diseases. The development demonstrates the first effective delivery of antibodies into cells, which could lead to novel drug treatments.
Two recent studies by University Hospitals Seidman Cancer Center have identified potential new treatments for small cell lung cancer, including a link between the RET mutation and sensitivity to targeted therapies.
A new study describes a mechanism for how cancer cells take over one of the processes for telomere maintenance, allowing them to gain an infinite lifespan. The team found that cancer cells use either telomerase or alternative lengthening of telomeres (ALT) mechanisms to maintain their telomeres.
Researchers at USC Keck Medicine have discovered a dual purpose of the cancer drug decitabine in regulating gene expression. The study found that the drug not only reactivated tumor suppressor genes but also down-regulated overexpressed oncogenes, which are responsible for cancer progression. This new mechanism may provide additional t...
Researchers redesigned a molecule to control immune cell activity, changing its target and altering the effects of its signal. This new approach may let scientists selectively block the bad signals that cause or contribute to disease, enhancing good signals that defend against cancer and infections.
Researchers at the University of Leicester have developed a breakthrough technique to generate synthetic amino acids and designer proteins, which can be used to develop innovative new protein drugs for cancer and Alzheimer's disease treatment. The discovery opens up new avenues for drug discovery with potentially highly potent drugs an...
The NCI/FDA workshop resulted in the development of two innovative clinical trials, Lung-MAP and ALCHEMIST, which employ a 'Master Protocol' approach to improve patient outcomes. These trials aim to accelerate the development of targeted therapies for lung cancer by integrating multiple sub-studies based on genomic profiles.
The Fashion Footwear Association of New York and QVC presented $240,000 to the University of Pittsburgh Cancer Institute for breast cancer research. The grant will fund research on why breast cancer recurs and metastasizes, a potentially major impact on breast cancer survival rates.
Researchers have discovered a new cancer drug target, TIPE3, which promotes tumor growth by hijacking lipid signaling pathways. Abnormal expression of TIPE3 has been linked to various types of cancer, including lung, colon, and ovarian cancers, making it a potential therapeutic target for treating malignant diseases.
Researchers have discovered that curcumin and peptides can increase levels of protein inhibitor PIAS3, which combats the progression of mesothelioma. This finding suggests that PIAS3 expression positively affects survival in mesothelioma patients, offering a potential therapeutic strategy.
A study from the University of Pennsylvania found that combining exercise with chemotherapy shrunk tumors more than chemotherapy alone in a mouse model of melanoma. Exercise increased blood flow to the tumor, bringing more of the drug into the bloodstream, and may help reduce side effects.
A study published in the Journal of Clinical Pathology suggests that adding a wild berry extract to chemotherapy cycles may improve treatment outcomes for pancreatic cancer. The researchers found that the extract induced cell death and boosted the effectiveness of the conventional drug gemcitabine.
Michigan State University scientists have discovered the first detailed examination of mutations similar to those present in the human cancer gene. The study reveals that boosting levels of even standard protein can alter fruit flies' eyes and wings, while mutated protein causes consistent and dramatic deformations.
Researchers found that chokeberry extract killed off cancer cells and boosted the effectiveness of chemotherapy drug gemcitabine in treating pancreatic cancer. The extract's anti-cancer properties were tested on human pancreatic cancer cells, with results suggesting a potential synergy between the two.
Researchers found that combining targeted radiation therapy (SBRT) with the drug cetuximab improved treatment outcomes for patients with recurrent squamous cell carcinoma of the head and neck. The study showed a significant reduction in severe toxicity, allowing patients to complete treatments faster.
A major new study shows that some prostate cancer treatments can stop working over time and even drive tumour growth. Researchers identified a 'treatment paradigm' using repeated blood samples to monitor signs of therapy becoming counter-productive.
Researchers propose epigenetic drugs to treat cancer resistance and relapse by modifying gene expression. Studies suggest epigenetic changes contribute to cancer progenitor cell formation, drug resistance, and relapse.
A study in mice implanted with breast and melanoma cancers found that combining radiation therapy with a checkpoint inhibitor increases antitumor responses from the immune system. The combination also enhances memory T-cells, which retain memory of the tumor and can attack it long after treatment.
Researchers found that cancer cells decorate their surfaces with glycans that can promote or inhibit cancer progression depending on the stage of the disease. The immune system may be a double-edged sword in cancer, with certain immune cell receptors binding to these glycans producing opposite outcomes.
Researchers developed a novel approach to target the activation of Ral proteins, which drive tumor growth in several human cancers. A compound called BQU57 proved most successful in slowing cancer cell growth and activation.
Researchers at Dartmouth's Geisel School of Medicine have found that the genetic mutation BRAFV600E promotes melanoma tumor growth by modifying normal cells around the tumor. Targeting this mutation with Vemurafenib reduces aggressive growth and suggests new treatment options for melanoma therapy.
The Phase I Clinical Trial of nintedanib combined with paclitaxel showed a 50% complete response rate in early HER-2-negative breast cancer patients. The study's results have validated the safety and efficacy of the drug combination, paving the way for a large-scale Phase II Clinical Trial.
A high-risk leukemia subtype known as Philadelphia chromosome-like ALL (Ph-like ALL) is becoming increasingly common in young adults, particularly with age. This subtype is associated with poor survival rates compared to other forms of acute lymphoblastic leukemia (ALL).
A new cancer drug targeting mitochondrial function has been proven safe and showed some efficacy in a Phase I clinical trial for leukemia patients. The drug selectively shut down energy production in cancer cells, which can reproduce faster and repair damage from chemotherapy.
Researchers at Sanford-Burnham Medical Research Institute have developed a novel technique to promote tissue repair in damaged muscles. Cyclic bursts of a STAT3 inhibitor can replenish muscle stem cells, leading to their differentiation into muscle fibers, which could provide a new therapeutic approach to treating muscle diseases.
Researchers at Memorial Sloan Kettering Cancer Center have successfully grown prostate cancer organoids from human tumors, providing a new tool for testing cancer drugs and personalizing treatment. The addition of these organoids doubles the number of existing prostate cancer cell lines, offering a more accurate representation of the d...
A blood test detecting the 'nicked' protein AR-V7 in prostate cancer patients can predict resistance to commonly used treatments enzalutamide and abiraterone. This biomarker may help tailor treatment strategies for men with detectable levels of AR-V7.
Researchers have developed an innovative algorithm that identifies synthetic lethal interactions in cancer, enabling personalized treatment and predicting patient prognosis. The study's findings show promise for repurposing existing drugs to target specific cancer types.
Researchers found that high out-out assortativity in transcription factor networks contributes to robustness, with similar numbers of outgoing connections among connected TFs. This signature is a predictor of robustness, with an above-average number of connected TFs exhibiting this property.
A new study confirms the role of invadopodia in cancer spread, showing that preventing their formation can stop cancer entirely. The study identifies a potential therapeutic target for drug development to prevent invadopodia formation.
The Translational Genomics Research Institute has received regulatory approval for a $5 million clinical trial study on glioblastoma. The pilot trial will test new drugs to extend GBM patient survival, while also analyzing genomic data from over 536 past cases and conducting lab tests to measure cell responses.